Cancer Chemotherapy and PharmacologyThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

960 records returned

Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Combined inhibition of IGFR signaling enhances the growth inhibitory and apoptosis-inducing effects of gefitinib, suggesting that this approach could be useful to overcome the primary resistance to EGFR-TKIs in lung cancer. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1174-7Authors Yun Jung Choi, Korea Institute of Radiological and Medical Science Department of Internal Medicine, Korea Cancer Center Hospital 215-4 Gongneung-dong, Nowon-gu Seoul 139-706 KoreaJin Kyung Rho, Korea Institute of Radiological and Medical Science Department of Internal Medicine, Korea...
Source: Cancer Chemotherapy and Pharmacology - November 18, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Can the 2-13C-uracil breath test be used to predict the effect of the antitumor drug S-1?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion These results suggest that the anticancer effect of S-1 can be predicted by performing UrBT 3 h after the initial oral S-1 administration. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1168-5Authors Yukimoto Ishii, Nihon University School of Medicine Department of Surgery, Nerima Hikarigaoka Hospital 2-11-1 Hikarigaoka Nerima-ku Tokyo 179-0072 JapanShigeru Suzuki, Nihon University School of Medicine Division of Genetic and Genomic Research, Medical Research Center Itabashi-ku Tokyo 173-8610 JapanYasuo Takahashi, Nihon University School of Medicine Division ...
Source: Cancer Chemotherapy and Pharmacology - November 18, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in ratsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Genomic analysis provided further evidence that mitochondria are the primary target of doxorubicin-induced oxidative damage that leads to cardiomyopathy and the primary site of cardioprotective action by dexrazoxane. Additional strategies that prevent the formation of oxygen radicals by doxorubicin in mitochondria may provide increased cardioprotection. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1164-9Authors Karol L. Thompson, US Food and Drug Administration Center for Drug Evaluation and Research LSB64 Room 2036, 10903 New Hampshire Avenue Silver Spring M...
Source: Cancer Chemotherapy and Pharmacology - November 13, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Renal impairment did increase the systemic exposure to arsenic and its methylated metabolites following standard daily dosing of arsenic trioxide. The data from the limited number of patients with severe renal dysfunction did not suggest that severe renal impairment affected the safety profile of arsenic trioxide in cancer patients who received limited treatment with arsenic trioxide. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1169-4Authors Christopher J. Sweeney, Indiana University Department of Medicine 535 Barnhill Drive, Rm 473 Indianapolis IN 46202 USA...
Source: Cancer Chemotherapy and Pharmacology - November 12, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Albendazole was well tolerated on the schedule tested in this trial. The results of this study suggest that the recommended dose for further study is 1,200 mg twice daily for 14 days in a 21-day cycle. Content Type Journal ArticleCategory Clinical Trial ReportDOI 10.1007/s00280-009-1157-8Authors Mohammad H. Pourgholami, University of New South Wales Department of Surgery, St George Clinical School Kogarah, Sydney AustraliaMichael Szwajcer, St George Hospital Cancer Care Cancer Pharmacology and Therapeutics Sydney AustraliaMelvin Chin, St George Hospital Cancer Care Cancer Pharma...
Source: Cancer Chemotherapy and Pharmacology - November 11, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion We established in vivo trastuzumab PD models, in which trastuzumab monotherapy ceases to have antitumor activity during the treatment. The mechanisms of PD with trastuzumab are considered to involve both reversible changes in the gene expression profiles in tumor tissues and a decrease of ADCC activity in the host. Our present results demonstrated that trastuzumab showed antitumor activity in combination with taxanes or capecitabine even though it showed no antitumor activity as a monotherapy, suggesting a clinical relevance of treatment with trastuzumab as a combination therapy beyond PD. ...
Source: Cancer Chemotherapy and Pharmacology - November 10, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this report, we describe a fatal gemcitabine-induced pulmonary toxicity in a patient with gallbladder metastatic adenocarcinoma. A 72-year-old patient was submitted to an elective laparoscopic cholecystectomy, and a tubular adenocarcinoma in the gallbladder was incidentally diagnosed. CT scan and ultrasound before the surgery did not show any tumor. After the surgery a Pet scan was positive for a hot-spot in the left colon. The colonic lesion was conveniently removed and the histology evaluation confirmed the diagnosis of adenocarcinoma tubular. The patient was then submitted to three sections of 1,600 mg/m2 of gem...
Source: Cancer Chemotherapy and Pharmacology - November 10, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Glutamine regulation of doxorubicin accumulation in hearts versus tumors in experimental ratsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions These data indicate that GLN supplement is able to reduce DOX-induced cardiac damage and thus to enhance DOX therapeutic effectiveness. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1165-8Authors Valentina K. Todorova, University of Arkansas for Medical Sciences (UAMS) Division of Breast Surgical Oncology, Department of Surgery 4301W, Markham St., Mail Slot 725 Little Rock AR USAYihong Kaufmann, Central Arkansas Veterans Healthcare System Little Rock AR USALeah J. Hennings, University of Arkansas for Medical Sciences (UAMS) Department of Pathology Little Rock AR...
Source: Cancer Chemotherapy and Pharmacology - November 7, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomasEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion UCN-01 can be safely administered in combination with prednisone without unacceptable toxicity. The prolonged stable disease in two patients with lymphoid malignancies is a proof of principle for the evaluation of cyclin-dependent kinase inhibitors in oncology. Content Type Journal ArticleCategory Clinical Trial ReportDOI 10.1007/s00280-009-1154-yAuthors Shivaani Kummar, National Cancer Institute Center for Cancer Research 10 Center Drive Bethesda MD 20892 USAMartin E. Gutierrez, National Cancer Institute Center for Cancer Research 10 Center Drive Bethesda MD 20892 USAErin R. Gardner, Scien...
Source: Cancer Chemotherapy and Pharmacology - November 5, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions The PSA response rate was promising and the toxicity of DGP was manageable; however OS was comparable to results of treatment with single agent docetaxel. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1163-xAuthors Trine Zeeberg Buch-Hansen, Herlev University Hospital Department of Oncology Herlev Ringvej 75 2730 Herlev DenmarkLise Bentzen, Aarhus University Hospital Department of Oncology Aarhus DenmarkSteinbjoern Hansen, Odense University Hospital Department of Oncology Odense DenmarkMorten Hoeyer, Aarhus University Hospital Department of Oncology Aarhus Denm...
Source: Cancer Chemotherapy and Pharmacology - October 31, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Synergistic activity of nilotinib and established chemotherapeutic drugs in imatinib-sensitive and -resistant BCR-ABL-positive cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract We investigated various combination treatment regimens employing nilotinib with established chemotherapeutic agents (daunorubicin, mitoxantrone, etoposide and cytarabine) in imatinib-sensitive and -resistant BCR-ABL-positive cells. Mitoxantrone or cytarabine showed synergism (CI < 1) in combination with nilotinib in imatinib-sensitive LAMA84 cells, whereas in imatinib-resistant LAMA84-R cells synergistic effects could be assessed for daunorubicin, mitoxantrone and etoposide when combined with nilotinib. In both imatinib-sensitive and -resistant K562 cells daunorubicin, mitoxantrone and ...
Source: Cancer Chemotherapy and Pharmacology - October 28, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions The recommended phase II dose of imexon is 875 mg/m² with gemcitabine 1,000 mg/m2. DLT was acute abdominal pain and cramping. Encouraging antitumor responses support further evaluation of this combination in advanced pancreatic cancer. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1162-yAuthors Steven J. Cohen, Fox Chase Cancer Center Department of Medical Oncology 333 Cottman Avenue, Room C307 Philadelphia PA 19111-2497 USAMark M. Zalupski, University of Michigan Ann Arbor USAManuel R. Modiano, Arizona Clinical Research Center Tucson USAPaul Conklin...
Source: Cancer Chemotherapy and Pharmacology - October 23, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Medulloblastoma in childhood: revisiting intrathecal therapy in infants and childrenEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions The pre-determined criteria were not applicable, in their entirety, in the majority of drugs, due to lack of information in the academic domain, emphasising the importance of a more open approach for sharing basic drug information. The prioritised list of 12 candidate drugs for clinical trial and 15 for pre-clinical investigation justify that a concerted research effort in this area of practice is made. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1127-1Authors Sharon Conroy, University of Nottingham Children’s Brain Tumour Research Centre University Park ...
Source: Cancer Chemotherapy and Pharmacology - October 23, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiformeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Concomitant radiotherapy–gemcitabine is active and well tolerated in newly diagnosed glioblastoma multiforme. Activity is observed both in tumors with methylated and unmethylated MGMT promoter. Content Type Journal ArticleCategory Clinical Trial ReportDOI 10.1007/s00280-009-1155-xAuthors Giulio Metro, Regina Elena Cancer Institute Division of Medical Oncology Via Elio Chianesi, 53 00144 Rome ItalyAlessandra Fabi, Regina Elena Cancer Institute Division of Medical Oncology Via Elio Chianesi, 53 00144 Rome ItalyMaria A. Mirri, Regina Elena Cancer Institute Division of Radiotherapy Rome Italy...
Source: Cancer Chemotherapy and Pharmacology - October 21, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Platinum-based therapies are vital to the treatment of primary peritoneal and ovarian carcinoma. Protocols that successfully incorporate platinum agents, despite a platinum hypersensitivity, are clinically relevant. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1159-6Authors Daniel P. Greene, University of Virginia School of Medicine Charlottesville VA USAJames Stuart Ferriss, University of Virginia Health System Thornton Gynecologic Oncology Service, Department of Obstetrics and Gynecology P.O. Box 800712 Charlottesville VA 22908 USAAmir A. Jazaeri, University...
Source: Cancer Chemotherapy and Pharmacology - October 21, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions The timing of clinical combination therapy doses is often selected empirically. PK/PD models provide a theoretical structure useful in the design of the optimal clinical dose, frequency of administration and the optimal timing of administration between anticancer agents to maximize tumor suppression. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1153-zAuthors Kosalaram Goteti, AstraZeneca R&D Boston Department of Drug Metabolism and Pharmacokinetics 35 Gatehouse Drive Waltham MA 02451 USAC. Edwin Garner, AstraZeneca R&D Boston Department of Drug Metabolism and...
Source: Cancer Chemotherapy and Pharmacology - October 20, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Although most patients had stage IV NPC, the TPF induction chemotherapy followed by CCRT showed promising activity with manageable toxicity. These results demonstrated the possibility of effective treatment with the aim of not only a palliative, but also a curative, approach to the treatment of advanced NPC. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1152-0Authors Woo Kyun Bae, Chonnam National University Medical School Department of Hematology-Oncology Gwangju 501-757 KoreaJun Eul Hwang, Chonnam National University Medical School Department of Hematology-O...
Source: Cancer Chemotherapy and Pharmacology - October 14, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Since 5-FU + NSAID treatment can alter the DPD enzyme activity resulting in an enhanced cytotoxic effect, further studies in clinical practice are warranted. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1149-8Authors Andrea Réti, National Institute of Oncology Department of Clinical Research Budapest HungaryÉva Pap, National Institute of Oncology Department of Clinical Research Budapest HungaryVilmos Adleff, National Institute of Oncology Department of Clinical Research Budapest HungaryAndrás Jeney, Semmelweis University 1st Institute of Pathology...
Source: Cancer Chemotherapy and Pharmacology - October 14, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Sensitivity of breast cancer cell lines to recombinant thiaminase IEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion These findings suggest that THTR2 down-regulation in breast tumors may present a nutritional vulnerability that could be exploited by thiaminase I enzyme therapy. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1148-9Authors Shuqian Liu, University of Kentucky College of Medicine Division of Pediatric Hematology-Oncology, Department of Pediatrics 740 S. Limestone Room J457 Lexington KY 40536 USANoel R. Monks, University of Kentucky College of Medicine Division of Pediatric Hematology-Oncology, Department of Pediatrics 740 S. Limestone Room J457 Lexington KY 40536 ...
Source: Cancer Chemotherapy and Pharmacology - October 14, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Peroxisome proliferator-activated receptor γ-dependent activity of indole ring-substituted 1,1-bis(3′-indolyl)-1-(p-biphenyl)methanes in cancer cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions The results demonstrate that DIM-C-pPhC6H5 and indole ring-substituted analogs are selective PPARγ modulators. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1144-0Authors Jingjing Guo, Texas A&M University Health Science Center Institute of Biosciences and Technology Houston TX USASudhakar Chintharlapalli, Texas A&M University Health Science Center Institute of Biosciences and Technology Houston TX USASyng-ook Lee, Texas A&M University Health Science Center Institute of Biosciences and Technology Houston TX USASung Dae Cho, Chonbuk National University Departmen...
Source: Cancer Chemotherapy and Pharmacology - October 13, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Survival benefit from ovarian metastatectomy in colorectal cancer patients with ovarian metastasis: a retrospective analysisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Based on this retrospective analysis, the ovarian metastatectomy significantly prolonged survival in CRC patients with ovarian metastases. The potential role of an ovarian metastatectomy in the management of CRC should be prospectively studied. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1150-2Authors Su Jin Lee, Samsung Medical Center, Sungkyunkwan University School of Medicine Division of Hematology/Oncology, Department of Medicine 50 Ilwon-dong Kangnam-gu Seoul 135-710 KoreaJeeyun Lee, Samsung Medical Center, Sungkyunkwan University School of Medicine Divi...
Source: Cancer Chemotherapy and Pharmacology - October 10, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

The effects of drug transporter inhibitors on the pharmacokinetics and tissue distribution of methotrexate in normal and tumor-bearing mice: a microdialysis studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions This study revealed significant differences in the relative estimated PK parameters of the plasma, SC, peri-, and intratumoral zones. Additionally, this study demonstrated that the coadministration of MTX with CsA can enhance the intratumoral exposure levels of the drug, whereas coadministration of MTX with probenecid alone, or with a combination of probenecid and CsA, increases intratumoral half-life. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1146-yAuthors Shabnam N. Sani, Massachusetts College of Pharmacy and Health Sciences Department of Pharmaceutical...
Source: Cancer Chemotherapy and Pharmacology - October 9, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Feasibility study for biweekly administration of cisplatin plus gemcitabine as adjuvant-chemotherapy for completely resected non-small cell lung cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion This regimen is feasible in the treatment of patients with completely resected NSCLC. A multicenter phase III trial is warranted to assess the efficacy of this regimen at promoting survival and preventing recurrence. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1139-xAuthors Masafumi Yamaguchi, Respiratory Center and Clinical Institute, National Hospital Organization Kyushu Medical Center Division of General Thoracic Surgery Jigyouhama 1-8-1, Chuou-ku Fukuoka 810-8563 JapanSadanori Takeo, Respiratory Center and Clinical Institute, National Hospital Organization...
Source: Cancer Chemotherapy and Pharmacology - October 7, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Relationship of mRNA expressions of RanBP2 and topoisomerase II isoforms to cytotoxicity of amrubicin in human lung cancer cell linesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Our in vitro results suggest that mRNA expressions of RanBP2 and TopoII isoforms are unlikely to be a predictive biomarker for the sensitivity to amrubicin. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1151-1Authors Yoshitsugu Horio, Aichi Cancer Center Hospital Department of Thoracic Oncology 1-1 Kanokoden, Chikusa-ku Nagoya 464-8681 JapanHirotaka Osada, Aichi Cancer Center Research Institute Division of Molecular Oncology 1-1 Kanokoden, Chikusa-ku Nagoya 464-8681 JapanJunichi Shimizu, Aichi Cancer Center Hospital Department of Thoracic Oncology 1-1 Kanokoden...
Source: Cancer Chemotherapy and Pharmacology - October 7, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Contrary to previous estimates for a UK population, genetic DPD deficiency accounts for around 19% of cases of severe fluoropyrimidine toxicity. The influence of DPD deficiency is such that toxicity can be avoided by prior testing and appropriate 5-FU dose/regimen alteration. Content Type Journal ArticleCategory Short CommunicationDOI 10.1007/s00280-009-1147-xAuthors Aathavan Loganayagam, Guy’s and St Thomas’ Hospital NHS Foundation Trust Department of Gastroenterology 1st Floor, College House, St Thomas’ Hospital, Lambeth Palace Road London SE1 7EH UKMonica Arenas-Hernandez, Guy’s...
Source: Cancer Chemotherapy and Pharmacology - September 30, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published dataEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Critical toxicity from NAD depleting cancer drugs to consider in future trials seems to be thrombocytopenia and various gastrointestinal symptoms. Efficacy of NAD depleting drugs when used alone is expected to be low. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1125-3Authors Anne von Heideman, Uppsala University Department of Oncology, Radiology and Clinical Immunology, Section of Oncology, University Hospital 751 85 Uppsala SwedenÅke Berglund, Uppsala University Department of Oncology, Radiology and Clinical Immunology, Section of Oncology, University Hospi...
Source: Cancer Chemotherapy and Pharmacology - September 29, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions The PK of RAD001 differed between mice and rats, with rats having a PK profile closer to that of humans. High intermittent doses of RAD001 may be more appropriate for treatment of brain tumors. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1068-8Authors Terence O’Reilly, Novartis Institutes for BioMedical Research Department of Oncology Research WKL-125.13.17 4002 Basel SwitzerlandPaul M. J. McSheehy, Novartis Institutes for BioMedical Research Department of Oncology Research WKL-125.13.17 4002 Basel SwitzerlandR. Kawai, Novartis Pharma AG Department of Drug ...
Source: Cancer Chemotherapy and Pharmacology - September 29, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Usefulness of chemotherapy beyond the second line for metastatic breast cancer: a therapeutic challengeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions These factors should help determine the appropriate strategy for proposing a third line of chemotherapy. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1141-3Authors Elodie Vauléon, Comprehensive Cancer Center, E Marquis Department of Medical Oncology CS 44229 Avenue de la Bataille Flandres Dunquerke 35042 Rennes cedex FranceHabiba Mesbah, Comprehensive Cancer Center, E Marquis Department of Medical Information CS 44229 35042 Rennes cedex FranceBrigitte Laguerre, Comprehensive Cancer Center, E Marquis Department of Medical Oncology CS 44229 Avenue de la Bataille...
Source: Cancer Chemotherapy and Pharmacology - September 29, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Effects of extracellular purines on cytotoxicity of methotrexateEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion These results add further evidence that purines present in normal culture conditions are important determinants of methotrexate cytotoxicity. Elevation of dATP levels after methotrexate treatment is an important modulator of cytotoxicity. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1142-2Authors Li Chong, The University of Sydney Department of Cancer Medicine, Blackburn Building D06 Sydney NSW 2006 AustraliaGuoyi Ma, The University of Sydney Department of Cancer Medicine, Blackburn Building D06 Sydney NSW 2006 AustraliaWendy A. Bartier, The University of Sydne...
Source: Cancer Chemotherapy and Pharmacology - September 29, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemiasEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Aminopterin does not appear to offer any advantage over methotrexate for the treatment of childhood ALL. Further study of pemetrexed in childhood leukemias is warranted. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1120-8Authors Robin E. Norris, Abramson Research Center Division of Clinical Pharmacology and Therapeutics, Children’s Hospital of Philadelphia 3615 Civic Center Blvd., Suite 916 Philadelphia PA 19104 USAPeter C. Adamson, Children’s Hospital of Philadelphia Division of Oncology, Division of Clinical Pharmacology and Therapeutics Philadelphia PA ...
Source: Cancer Chemotherapy and Pharmacology - September 29, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

High endoplasmic reticulum activity renders multiple myeloma cells hypersensitive to mitochondrial inhibitorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Multiple myeloma (MM) cells continuously secrete large amounts of immunoglobulins that are folded in the endoplasmic reticulum (ER) whose function depend on the Ca2+ concentration inside its lumen. Recently, it was shown that the ER membrane leaks Ca2+ that is captured and delivered back by mitochondria in order to prevent its loss. Thus, we hypothesized that the highly active and abundant ER in MM cells results in greater Ca2+-regulation by mitochondria which would render them sensitive to mitochondrial inhibitors. Here, we indeed find that Ca2+ leak is greater in 3 MM, when compared to 2 B-cell leuk...
Source: Cancer Chemotherapy and Pharmacology - September 24, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor modelsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Folate-targeting confers a significant albeit modest therapeutic improvement to PLD in FR-expressing tumor models, which appears particularly valuable in intracavitary therapy. The potential clinical added value of this approach has yet to be determined. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1132-4Authors Alberto Gabizon, Shaare Zedek Medical Center Experimental Oncology Laboratory 11 Shmuel Bayit Street, 7th Floor P.O. Box 3235 Jerusalem 91031 IsraelDina Tzemach, Shaare Zedek Medical Center Experimental Oncology Laboratory 11 Shmuel Bayit Street, 7th Fl...
Source: Cancer Chemotherapy and Pharmacology - September 24, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Bexarotene: a promising anticancer agentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Retinoids are biologically active derivatives of vitamin A, which play essential roles in embryonic or adult cell behavior modulating cell proliferation, differentiation and apoptosis. The biologic effects of retinoids are mediated by two distinct families of intracellular receptors: retinoid acid receptors (RARs)-α, -β and -γ and retinoid X receptors (RXR)-α, -β and -γ. Bexarotene is a selective RXR agonist, which exerts its effects in blocking cell cycle progression, inducing apoptosis and differentiation, preventing multidrug resistance, and inhibiting angiogenesis and metastasis, making it...
Source: Cancer Chemotherapy and Pharmacology - September 24, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in miceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion We conclude that SN 28049’s high tumour exposure and long tumour retention time is likely to contribute to its high antitumour activity in vivo. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1123-5Authors Pradeep B. Lukka, The University of Auckland Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences Private Bag 92019 Auckland New ZealandJames W. Paxton, The University of Auckland Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences Private Bag 92019 Auckland New ZealandPhilip Kestell, The Uni...
Source: Cancer Chemotherapy and Pharmacology - September 23, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Sequential paclitaxel and bortezomib in previously treated patients with advanced solid tumors resulted in acceptable toxicity and no evidence of interaction. The recommended phase II dose of bortezomib in combination with weekly paclitaxel was 1.8 mg/m2. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1145-zAuthors Bhuvaneswari Ramaswamy, The Ohio State University B401, Starling Loving Hall, 320 W 10th av Columbus OH 43210 USATanios Bekaii-Saab, The Ohio State University B401, Starling Loving Hall, 320 W 10th av Columbus OH 43210 USALarry J. Schaaf, The Oh...
Source: Cancer Chemotherapy and Pharmacology - September 23, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions The combination had moderate, but manageable toxicity. In the future studies, lower dose for capecitabine is recommended. The combination was active and the response rates seen here were in line with phase-II studies on former combinations of non-pegylated interferons. One complete remission was achieved. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1134-2Authors Kaisa Leea Sunela, Tampere University Hospital Department of Oncology P.O. Box 2000 33521 Tampere FinlandSanna Koskinen, University of Tampere Medical School, University of Tampere Department of Onco...
Source: Cancer Chemotherapy and Pharmacology - September 21, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Together, these results show that blockage of AT1 receptor signaling may be a promising anti-tumor strategy, interfering with angiogenesis by decreasing the expression of angiogenic factor receptors. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1136-0Authors Andréia Hanada Otake, Faculdade de Medicina da Universidade de São Paulo Laboratório de Oncologia Experimental (LIM-24), Departamento de Radiologia e Instituto do Câncer do Estado de São Paulo Av. Dr. Arnaldo, 455 room 4112/4122 São Paulo SP 01246-903 BrazilAna Lucia Mattar, Departamento de Clínica ...
Source: Cancer Chemotherapy and Pharmacology - September 21, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Heterogeneity of epithelial and stromal cells of head and neck squamous cell carcinomas in ex vivo chemoresponseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions The ex vivo chemoresponse of EC and SC of HNSCC must be analyzed separately. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1124-4Authors Iris-Susanne Horn, University Hospital Leipzig Department of Otorhinolaryngology, Head and Neck Surgery Liebigstraße 10-14 04103 Leipzig GermanyGunnar Wichmann, University Hospital Leipzig Department of Otorhinolaryngology, Head and Neck Surgery Liebigstraße 10-14 04103 Leipzig GermanyChristian Mozet, University Hospital Leipzig Department of Otorhinolaryngology, Head and Neck Surgery Liebigstraße 10-14 04103 Leipzig Germany...
Source: Cancer Chemotherapy and Pharmacology - September 21, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Gef gene therapy enhances the therapeutic efficacy of doxorubicin to combat growth of MCF-7 breast cancer cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions The cytotoxic effect of gef gene in breast cancer cells enhances the chemotherapeutic effect of doxorubicin. This therapeutic approach has the potential to overcome some of the major limitations of conventional chemotherapy, and may therefore constitute a promising strategy for future applications in breast cancer therapy. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1135-1Authors Jose Prados, University of Granada Department of Human Anatomy and Embryology, School of Medicine, Institute of Biopathology and Regenerative Medicine (IBIMER) 18071 Granada SpainCo...
Source: Cancer Chemotherapy and Pharmacology - September 21, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Certain transporter genotypes additively increased irinotecan-induced neutropenia, but their clinical importance should be further elucidated. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1138-yAuthors Kimie Sai, National Institute of Health Sciences Division of Functional Biochemistry and Genomics 1-18-1 Kamiyoga, Setagaya-ku Tokyo 158-8501 JapanYoshiro Saito, National Institute of Health Sciences Division of Functional Biochemistry and Genomics 1-18-1 Kamiyoga, Setagaya-ku Tokyo 158-8501 JapanKeiko Maekawa, National Institute of Health Sciences Division of F...
Source: Cancer Chemotherapy and Pharmacology - September 21, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Phase I study of combination therapy with weekly paclitaxel and cyclophosphamide for advanced or recurrent breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Safety was well tolerated throughout the four courses at level 2, and this dosage level was therefore regarded as the RD. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1137-zAuthors Norikazu Masuda, Osaka National Hospital Breast Oncology Group, Department of Surgery 2-1-14, Honenzaka, Chuo-ku Osaka Osaka 540-0006 JapanTakahiro Nakayama, Osaka University Department of Breast and Endocrine Surgery, Graduate School of Medicine Suita JapanJun Yamamura, Osaka National Hospital Breast Oncology Group, Department of Surgery 2-1-14, Honenzaka, Chuo-ku Osaka Osaka 540-00...
Source: Cancer Chemotherapy and Pharmacology - September 18, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

PSC833, cyclosporine analogue, downregulates MDR1 expression by activating JNK/c-Jun/AP-1 and suppressing NF-κBEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions These results indicate that PSC833 not only sensitizes SK-MES-1/DX1000 cells to doxorubicin by enhancing drug accumulation, but also downregulates MDR1 expression by activating JNK/c-Jun/AP-1 and suppressing NF-κB. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1121-7Authors H. Bark, Chosun University Medical School Department of Pharmacology, Research Center for Resistant Cells 375 Seosuk-dong Dong-gu Gwangju 501-759 KoreaCheol-Hee Choi, Chosun University Medical School Department of Pharmacology, Research Center for Resistant Cells 375 Seosuk-dong Dong-gu Gwa...
Source: Cancer Chemotherapy and Pharmacology - September 17, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Docetaxel plus cisplatin combination chemotherapy showed promising antitumor activity with manageable toxicities in patients with metastatic squamous esophageal cancer. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1130-6Authors Jin Young Kim, Keimyung University School of Medicine Division of Oncology-Hematology, Department of Internal Medicine, Dongsan Medical Center 194, Dongsan-dong, Jung-gu Daegu 700-712 KoreaYoung Rok Do, Keimyung University School of Medicine Division of Oncology-Hematology, Department of Internal Medicine, Dongsan Medical Center 194, Don...
Source: Cancer Chemotherapy and Pharmacology - September 17, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Both HAIC regimens are safe and effective in patients with advanced HCC. High-dose HAIC achieves a better tumor response compared to low-dose HAIC. Content Type Journal ArticleCategory Clinical Trial ReportDOI 10.1007/s00280-009-1126-2Authors Hyun Young Woo, Pusan National University Department of Internal Medicine, College of Medicine Busan KoreaSi Hyun Bae, The Catholic University of Korea Division of Hepatology, Department of Internal Medicine, College of Medicine #505 Banpodong, Seochogu Seoul 137-040 KoreaJun Yong Park, Yonsei University College of Medicine Department of Internal Medic...
Source: Cancer Chemotherapy and Pharmacology - September 17, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Meta-analysis of incidence and risk of hypokalemia with cetuximab-based therapy for advanced cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Cetuximab-based therapy is associated with a significant risk of hypokalemia. Early monitoring and effective management of hypokalemia is important for patients that received cetuximab-based therapy. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1131-5Authors Yunfei Cao, Guangxi Medical University Department of Colorectal and Anal Surgery, First Affiliated Hospital Nanning Guangxi People’s Republic of ChinaLidan Liu, Guangxi Medical University Department of Colorectal and Anal Surgery, First Affiliated Hospital Nanning Guangxi People’s Republic of ChinaCun L...
Source: Cancer Chemotherapy and Pharmacology - September 17, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case seriesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Zoledronic acid may be helpful in treating bone metastases in HCC patients. Patients regularly receiving zoledronic acid showed significant pain relief. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1122-6Authors Liliana Montella, “San Giovanni di Dio” Hospital Medical Oncology Unit via Domenico Pirozzi Frattamaggiore Naples ItalyRaffaele Addeo, “San Giovanni di Dio” Hospital Medical Oncology Unit via Domenico Pirozzi Frattamaggiore Naples ItalyGiovannella Palmieri, University “Federico II” Department of Molecular and Clinical Endocrinology and Onco...
Source: Cancer Chemotherapy and Pharmacology - September 17, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitroEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Dihydroartemisinin is a potent compound against LLC cell line in vitro. In vivo, the combination strategy of DHA and chemotherapeutics holds promise for the treatment of relatively large and rapidly growing lung cancers. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1129-zAuthors Hui-Jun Zhou, Zhejiang University Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences 388 Yuhang’tang Road Hangzhou Zhejiang 310058 People’s Republic of ChinaJia-Li Zhang, Zhejiang University Institute of Pharmacology and Toxicology, College of Pharmaceutic...
Source: Cancer Chemotherapy and Pharmacology - September 16, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Oxidative stress and enhanced paracellular permeability in the small intestine of methotrexate-treated ratsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions NAC protected the small intestine of rats from MTX-induced change in paracellular permeability, suggesting that ROS played an important role in the enhanced paracellular permeability. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1119-1Authors Tomoko Maeda, Chiba University Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences 1-8-1 Inohana, Chuo-ku Chiba 260-8675 JapanYuko Miyazono, Chiba University Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences 1-8-1 Inohana, Chuo-ku Chiba 260-8675 JapanKousei Ito, The Universi...
Source: Cancer Chemotherapy and Pharmacology - September 16, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

N3-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FUEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion These results demonstrate that TFU is a promising prodrug of 5-FU for cancer treatment via sustained release of 5-FU in liver. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1128-0Authors Xiaofan Zhang, Shandong University Department of Pharmacology, School of Pharmaceutical Sciences Jinan ChinaJulia Li Zhong, Chongqing University The Base of “111 Project” for Biomechanics and Tissue Repair Engineering, Bioengineering College Chongqing ChinaWei Liu, Jinan Institute for Drug Control Jinan ChinaZuhua Gao, University of Calgary Calgary Laboratory Services, Depart...
Source: Cancer Chemotherapy and Pharmacology - September 16, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals

Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions This is the first detailed study to show that an increased anti-tumour effect is generated when doxorubicin and zoledronic acid are given in sequence in both hormone-sensitive and insensitive prostate cancer cells in vitro. Our results suggest that combined treatment with these agents is superior to single agent therapy, and should be explored in a tumour model of prostate cancer. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-009-1106-6Authors Rhys D. Clyburn, University of Sheffield Academic Unit of Clinical Oncology, School of Medicine and Biomedical Sciences B...
Source: Cancer Chemotherapy and Pharmacology - September 16, 2009 Category: Cancer & Oncology Tags: Cancer Chemotherapy and Pharmacology Source Type: journals